TX-EAGLE-EYE-NETWORKS
30.9.2021 13:02:11 CEST | Business Wire | Press release
Eagle Eye Networks, the global leader in cloud video surveillance, today announced the acquisition of artificial intelligence leader Uncanny Vision, accelerating the company’s leadership in providing AI and analytics to make customers’ businesses more efficient and the world a safer place. The acquisition also includes research and development capabilities and a new regional office in Bangalore, India.
“After evaluating more than a dozen AI companies, we began working with Uncanny Vision in 2020. It didn’t take long for us to conclude that Uncanny Vision is the clear leader in surveillance AI,” said Dean Drako, Eagle Eye Networks CEO. “Their award-winning AI technology is deployed across thousands of locations, including Fortune 500 customers.”
The deal accelerates Eagle Eye’s plan, announced in November 2020 , when Eagle Eye raised funds from venture capital firm Accel, to dramatically reshape video surveillance.
Uncanny Vision’s deep learning algorithms enable recognition, identification, and prediction, improving business operations, customer service, and site safety. Uncanny Vision’s award-winning AI is used today in multiple applications, including:
- Smart parking
- Retail analytics
- Gate security
- Toll automation
- Smart cities
- ATM monitoring
- Worker safety
- Perimeter security
Drako said, “Uncanny Vision’s tools for training, building, and optimizing models, and its infrastructure for managing and storing training data are superior. This is a key component we’re excited to add to the Eagle Eye Networks platform.”
All 60 Uncanny Vision employees will be retained, and Eagle Eye plans to expand the Bangalore office. Eagle Eye is committed to supporting Uncanny Vision’s current customers, and will continue to build its global infrastructure to provide the very best 24/7 support to its valued customers around the world.
Uncanny Vision co-founders, Ranjith Parakkal and Navaneethan Sundaramoorthy, have joined the Eagle Eye leadership team. Parakkal said, “We share the Eagle Eye team’s vision to deliver advanced, cyber secure AI cloud video surveillance offerings that transform video surveillance for businesses around the globe.”
"The economic model of delivering subscription-based AI on a per-camera basis through a global cloud infrastructure will ignite growth for security integrators who are otherwise challenged with how to build a financially stable business," said Alper Cetingok, Managing Director and Head of the Security & Safety Practice at Raymond James.[1]
ABOUT EAGLE EYE NETWORKS
Eagle Eye Networks is No. 1 in cloud video surveillance worldwide. Our 100% cloud managed solutions provide cloud and on-premises recording, bank-level security and encryption, and broad analog and digital camera support – all accessed via the web or mobile applications. Eagle Eye Networks delivers cyber secure cloud-based video with artificial intelligence (AI) and analytics to make businesses more efficient and the world a safer place. All products benefit from Eagle Eye’s developer friendly RESTful API platform and Big Data Video FrameworkTM . Headquartered in Austin, Texas, Eagle Eye has offices in Bangalore, Tokyo, and Amsterdam. For more information, visit www.een.com .
ABOUT UNCANNY VISION
Founded in 2013, Uncanny Vision is an award-winning AI-based computer vision company delivering next generation intelligent surveillance solutions for smart cities, smart buildings and infrastructure specifically for people and vehicle monitoring using cameras. Uncanny Vision surveillance enables cameras to "see" and "understand" their environment instantly, using optimized real-time AI/deep learning algorithms. For more information, visit www.uncannyvision.com .
[1] Raymond James & Associates was not a party to the transaction.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210930005143/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom